The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
Open accessAbstract
Background Lowering of LDL cholesterol reduces major vascular events, but whether more intensive therapy safely produces extra benefits is uncertain. We aimed to establish efficacy and safety of more intensive statin treatment in patients at high cardiovascular risk.Methods We undertook a double-blind randomised trial in 12,064 men and women aged 18-80 years with a history of myocardial infarction. Participants were either currently on or had clear indication for statin therapy, and had a total cholesterol concentration of at least 3·5 mmol/L if already on a statin or 4·5 mmol/L if not. Randomisation to either 80 mg or 20 mg simvastatin daily was done centrally using a minimisation algorithm. Participants were assessed at 2, 4, 8, and 12 months after randomisation and then every 6 months until final follow-up. The primary endpoint was major vascular events, defined as coronary death, myocardial infarction, stroke, or arterial revascularisation. Analysis was by intention to treat. This study is registered, number ISRCTN74348595.Findings 6031 participants were allocated 80 mg simvastatin daily, and 6033 allocated 20 mg simvastatin daily. During a mean follow-up of 6·7 (SD 1·5) years, allocation to 80 mg simvastatin produced an average 0·35 (SE 0·01) mmol/L greater reduction in LDL cholesterol compared with allocation to 20 mg. Major vascular events occurred in 1477 (24·5%) participants allocated 80 mg simvastatin versus 1553 (25·7%) of those allocated 20 mg, corresponding to a 6% proportional reduction (risk ratio 0·94, 95% CI 0·88-1·01; p=0·10). There were no apparent differences in numbers of haemorrhagic strokes (24 [0·4%] vs 25 [0·4%]) or deaths attributed to vascular (565 [9·4%] vs 572 [9·5%]) or non-vascular (399 [6·6%] vs 398 [6·6%]) causes. Compared with two (0·03%) cases of myopathy in patients taking 20 mg simvastatin daily, there were 53 (0·9%) cases in the 80 mg group.Interpretation The 6% (SE 3·5%) reduction in major vascular events with a further 0·35 mmol/L reduction in LDL cholesterol in our trial is consistent with previous trials. Myopathy was increased with 80 mg simvastatin daily, but intensive lowering of LDL cholesterol can be achieved safely with other regimens.Funding Merck; The Clinical Trial Service Unit also receives funding from the UK Medical Research Council and the British Heart Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“based on the results of the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial the US Food and Drug Administration has announced new safety recommendations for high-dose simvastatin treatment owing to an associated elevated risk of muscle injury or myopathy75.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
Cited by
Sorted by citations
Items 401–500 of 557
Chressanthis, G. A., Khedkar, P., Jain, N., Poddar, P., & Seiders, M. G. (2011) · Journal of Pharmaceutical Health Services Research · doi:10.1111/j.1759-8893.2011.00064.x · Cited by 4
High-Potency Statins and Acute Kidney Injury–Associated Hospitalizations
Lenihan, C. R., & Lafayette, R. A. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.07.006 · Cited by 4
Bays, H. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.006 · Cited by 4
Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease
Benge, C. D., Markley, B. M., & McFarland, M. S. (2011) · Southern Medical Journal · doi:10.1097/smj.0b013e31823c4242 · Cited by 4
“Key Words: coronary arterydisease, hydroxymethylglutaryl-coenzyme a reductase inhibitors, lipoproteins, low-density lipoprotein Following the publication of the Third Report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adu…”
MethodInfluentialBellosta, S., Corsini, A., & Ferri, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-33304-1_7 · Cited by 4
Kim, Y. H., Her, A., Jeong, M. H., Kim, B., Hong, S., Kim, S., Ahn, C., Kim, J., Ko, Y., Choi, D., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02198-w · Cited by 4
Common statin side effects explain poor compliance
Dimmitt, S. B., Stampfer, H. G., & Warren, J. B. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12594 · Cited by 4
Drexel, H. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx030 · Cited by 4
[Efficacy and safety of atorvastatin in major cardiovascular events: Meta-analysis]
Villegas-Quintero, V. E., Rivas-Ruíz, R., García-Rivero, A. A., Rivera-Lara, P., & Tovar, N. B. G. (2023) · PubMed Central · doi:10.5281/zenodo.8319747 · Cited by 3
Excessive range of statin dose in W estern A ustralian primary care
Dimmitt, S. B., Moran, A., Scartozzi, M., Stampfer, H. G., & Warren, J. B. (2015) · Internal Medicine Journal · doi:10.1111/imj.12787 · Cited by 3
Dippel, F. W., Parhofer, K. G., Müller-Bohn, T., Gebhardt, S., & Kostev, K. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-123977 · Cited by 3
Expert group from the Spanish Arteriosclerosis Society, Pedro‐Botet, J., López‐Miranda, J., Badimón, L., Civeira, F., Guijarro, C., Millán, J., Mostaza, J. M., Pintó, X., Valdivielso, P., et al. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00376-y · Cited by 3
A mini-review to the common adverse-effects of statins
Nasri, H. (2022) · Journal of Renal Endocrinology · doi:10.34172/jre.2022.25071 · Cited by 3
Chung, J., Kim, H., Lim, W., Seo, J.-B., Zo, J., Kim, M., & Kim, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-42277-w · Cited by 3
Transparency in Science Reporting: A Call to Researchers and Publishers
Sturmberg, J. P., & Kühlein, T. (2025) · Cureus · doi:10.7759/cureus.79493 · Cited by 3
Pan, M., Deng, Y., Zheng, C., Nie, H., Tang, K., Zhang, Y., & Yang, Q. (2019) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2019.100950 · Cited by 3
Rusconi, C., Raddino, R., Trichaki, E., & Dei, L. (2011) · InTech eBooks · doi:10.5772/16560 · Cited by 3
Optimal lipid targets for the new era of cardiovascular prevention
Ramjee, V., Eapen, D. J., & Sperling, L. S. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06478.x · Cited by 3
Ebisawa, S., Izawa, A., Ueki, Y., Hioki, H., Minamisawa, M., Hashizume, N., Abe, N., Kashima, Y., Miura, T., Takeuchi, T., et al. (2015) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2015.07.007 · Cited by 3
Statins, cholesterol depletion and risk of incident diabetes
Mascitelli, L., & Goldstein, M. R. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.08.023 · Cited by 3
Torón, P. Á. O., Farré, T. B., & Lliso, A. R. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.12.002 · Cited by 3
Efficacy of folic acid in primary prevention of stroke among patients with hypertension in China
Goel, S., & Messerli, F. H. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.08.007 · Cited by 3
Couvert, P., Chapman, M. J., & Carrié, A. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.214 · Cited by 3
Statin/ezetimibe combination therapy: emerging evidence
Kalhan, A., & Rees, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283447835 · Cited by 3
Jun, Y., Huan, W., & Haotong, Y. (2025) · Sports medicine research and practice · doi:10.47529/2223-2524.2025.2.3 · Cited by 2
Soverow, J. E., & Watson, K. E. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0432-2 · Cited by 2
Future Pharmacological Therapies of Portal Hypertension
Ortiz, G. A., & García–Tsao, G. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00448-2 · Cited by 2
Jin, S., Nie, X., Li, Y., Yuan, J., Cui, Y., & Zhao, L. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.019 · Cited by 2
Zheng, J., Hou, Z., Yuan, J., Zhao, X., Wang, Y., Li, J., Zhang, W., Dou, K., & Lü, B. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070832 · Cited by 2
Sychev, D. A., Оstroumova, Т. М., Ostroumova, O. D., Кочетков, А. И., Владимировна, Б. С., & Mironova, E. V. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-3-252-270 · Cited by 2
Costa, A., Medeiros, J. I. M., Kang, W.-H., Yamamoto, P. A., de Gaitani, C. M., Vasconcelos, M. E. D., da Silva, R. M., Kemp, R., Sankarankutty, A. K., Salgado, W., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6110 · Cited by 2
van Bruggen, F. H., de Haas, E. C., Zuidema, S. U., & Luijendijk, H. J. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00668-y · Cited by 2
“1) [26–34].”
Ortendahl, J. D., Harmon, A. L., Bentley, T. G. K., & Broder, M. S. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1336449 · Cited by 2
Furuya‐Kanamori, L., Stone, J., & Doi, S. A. R. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.02.012 · Cited by 2
Statins: Is There an Increased Risk of Diabetes?
Kolich, M. N., & Howard, P. A. (2012) · Hospital Pharmacy · doi:10.1310/hpj4707-513 · Cited by 2
“the Pravastatin or Atorvastatin Evaluation and Infection Trial (PROVE-IT TIMI 22),(14) Aggrastat to Zocor (A to Z),(15) and the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) were pooled.(16) For this meta-analysis, data were collected for 32,752 patients without diabetes…”
MethodThe efficacy and cost-effectiveness of statins in low-risk patients
Gupta, A. K. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.111674 · Cited by 2
Zhang, T., Wu, W., Liu, Y., Wang, Q., Wang, L., & Mi, S.-H. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20122926 · Cited by 2
“Additionally, it has also been shown that a significant reduction in cholesterol levels can prevent or reverse atherosclerotic lesion progression.(4) A study using intravascular ultrasound has shown that when the concentration of serum LDL-C was less than 75 mg/dl, the progression of atherosclerotic lesions was delaye…”
BackgroundPedro‐Botet, J., & Pintó, X. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.10.006 · Cited by 2
Lipid-lowering drugs and control of hypercholesterolemia in Poland: recent evidence
Jankowski, P., Kloch‐Badełek, M., & Dębicka‐Dąbrowska, D. (2011) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1049 · Cited by 2
Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease
Almarzooq, Z., & Singh, P. (2016) · InTech eBooks · doi:10.5772/64762 · Cited by 2
“Different statins possess varying risk to cause muscle injury, with fluvastatin exhibiting the lowest risk and simvastatin exhibiting a higher risk of muscle injury, especially at 80 mg/day dose, as shown in the SEARCH trial that was the basis of the FDA restriction of this dose of simvastatin [64, 70, 75].”
BackgroundComplications musculaires des statines
Vergès, B. L. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.07.007 · Cited by 2
Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice
Abdelfattah, O., Hassanein, M., Saad, A. M., Abela, G. S., & Aldasouqi, S. A. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200107103829 · Cited by 2
McKenney, J. M., & Roth, E. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00021-9 · Cited by 2
The case for more intensive use of statins
Fulcher, J., & KEECH, A. C. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312454045 · Cited by 2
Dimmitt, S. B., & Martin, J. H. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50324 · Cited by 2
Vitamin D Deficiency in Muscle
Abou‐Al‐Shaar, H., Hakoun, A. M., & Bohlega, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-06731-0_11 · Cited by 1
Guo, B., Li, H.-B., Zhao, B., & Xu, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf336 · Cited by 1
U-Shaped Lipid-CVD Links in Older Adults
Ye, X., Du, S., Chen, S., Shi, Y., Wang, W., Wan, Y., Wang, J., Zeng, J., Pan, C., Yang, S., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102544 · Cited by 2
Statin wars: efficacy vs. cost
Wierzbicki, A. S. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02586.x · Cited by 1
Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis
Puri, R., Duong, M., Kataoka, Y., Uno, K., & Nicholls, S. J. (2012) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-012-0284-7 · Cited by 1
Are add-on agents to statin therapy necessary in hypercholesterolemia?
Dayer-Berenson, L., Finckenor, M., & Tuzzolino, M. (2014) · Clinical Lipidology · doi:10.2217/clp.14.57 · Cited by 1
Thomas, T. F. (2012) · Clinical Lipidology · doi:10.2217/clp.12.35 · Cited by 1
LDL cholesterol: should guidelines include targets?
Banerjee, S., Kahali, D., Banerjee, A., & Brilakis, E. S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.874284 · Cited by 1
“With low dose (20–40 mg) of simvastatin daily, the risk of myopathy is low (~1/10,000 patients per annum), but it increases 10-fold with 80 mg simvastatin daily to 1/1,000 patients per annum [15].”
BackgroundPesaro, A. E. P., Granger, C. B., & Lópes, R. D. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.11.001 · Cited by 1
Lipid Lowering in Coronary Artery Disease
Ray, K. K., & Cannon, C. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2358-8.00010-3 · Cited by 1
Parkin, L., SHARPLES, K. J., Barson, D. J., & Blank, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182066 · Cited by 1
Statin Safety: What Every Health Care Provider Needs to Know
Hashi, S., Sathiyakumar, V., Byrne, K., Elshazly, M. B., Jones, S. R., & Martin, S. S. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0565-x · Cited by 1
Statin‐associated muscle symptoms: Does the benefit outweigh the risk factor?
LaBoy, S. M., & Pulley, M. (2019) · Muscle & Nerve · doi:10.1002/mus.26470 · Cited by 1
Kellick, K. A., & Saseen, J. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_11 · Cited by 2
Moon, I. T., Kang, S., Lee, W., Cho, Y., Park, J. J., Yoon, Y. E., Oh, I., Yoon, C., Suh, J., Youn, T., et al. (2021) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2021.08.005 · Cited by 1
Schaefer, J., & Jackson, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-29514-5_8 · Cited by 1
(2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0738-6.00007-3 · Cited by 1
Inclisiran: new era of lipid-lowering therapy?
Beneš, J. (2023) · Cor et Vasa · doi:10.33678/cor.2022.043 · Cited by 1
Rauf, R., Soomro, M. I., Khan, M. N., Kumar, M., Soomro, N. A., & Kazmi, K. A. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i5.282 · Cited by 1
Sallam, M., Hassan, H., Connolly, D. L., & Rahman, M. S. (2024) · European Cardiology Review · doi:10.15420/ecr.2024.06 · Cited by 1
Lipid control and associated risk factors, before suffering from the first cardiovascular event
Torón, P. Á. O., Farré, T. B., & Lliso, A. R. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.12.002 · Cited by 1
Statin-Associated Muscle Symptoms Are Real
Toth, P. P. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-33304-1_2 · Cited by 1
Statins for secondary prevention: might less in fact be more?
Muñoz, D., & Blumenthal, R. S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.17 · Cited by 1
Catapano, A. L., Norata, G. D., & Pirillo, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328348a513 · Cited by 1
Polypill for prevention of cardiovascular diseases
Dimmitt, S. B., & Stampfer, H. G. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33002-8 · Cited by 1
DISCOVERY AND DEVELOPMENT OF ISOZYME‐SELECTIVE INHIBITORS INVOLVED IN LIPID METABOLISM
Ohshiro, T., & Tomoda, H. (2013) · Wiley eBooks · doi:10.1002/9781118739907.ch2
Metabolic and Endocrine Management of the Organ Transplant Recipient
Issa, N. S., Reule, S. A., & Kukla, A. (2014) · doi:10.1002/9781118873434.ch100
Cholesterol Metabolism and Vascular Disease
Wainwright, P., Ryan, A., Olufadi, R., & Byrne, C. D. (2015) · Wiley eBooks · doi:10.1002/9780470015902.a0002264.pub3
Drugs that affect lipid metabolism
Nestel, P. J. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00044-1
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Little, P. J., Chait, A., Januszewski, A. S., Bobik, A., O'Neal, D. N., & Jenkins, A. J. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_23
La fin du jeûne?: Mise à jour sur la préparation des patients pour une analyse du cholestérol
Naugler, C. T., & Sidhu, D. (2014) · PubMed Central
Iperlipoproteinemie: diagnosi e trattamento
Farnier, M. (2012) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(12)62070-1
Hiperlipoproteinemias: diagnóstico y tratamiento
Farnier, M. (2012) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(12)61917-5
Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence
Jimenez, J. G., & Haft, G. (2014) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s50952
Statins before stents: Does an ounce of prevention improve outcomes?
Frey, P., & Waters, D. D. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70453-0
Introducción: estatinas y salud cardiovascular
Badimón, L. (2011) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(11)12001-4
Comprehensive Lipid Management in the Coronary Artery Disease Patient
Amin, N. P., Blaha, M. J., Chow, G. V., Blumenthal, R. S., & Ashen, M. D. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0191-3
Clinical trials of lipid-modifying agents:design considerations
Bowman, L. J., Haynes, R., & Armitage, J. (2011) · Clinical Lipidology · doi:10.2217/clp.10.74
Controlling lipids after acute coronary syndromes: what is the best strategy?
Déry, J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.15
¿Es necesario reducir aún más el colesterol-LDL en prevención secundaria?
Solanas, P. (2014) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(14)70821-7
Brito, J. P., & Montori, V. M. (2014)
Should a Trial with Lost Allocation Key be Incorporated in Meta-analysis?
Pijls, B. G. C. W., van der Burg, B. L. S. B., Frisch, L., Vochteloo, A. J. H., & Nelissen, R. G. H. H. (2015) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2015/17815
“1 confirms that SEARCH-A has a correctly-assigned AK [7,6].”
BackgroundMethodStatin prescribing in Australian and Irish general practice:a qualitative study
Montgomery, B. (2012) · UWA Profiles and Research Repository (University of Western Australia)
Pharmacist-managed protocol to implement simvastatin labeling changes in a family medicine clinic
Harris, I. M., Philbrick, A. M., Fallert, C. J., & Soliman, A. M. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130459
Effective Lipid-lowering Therapy in High-risk Patients
Kastelein, J. J. P., Arsenault, B. J., & Tardif, J. (2011) · European Journal of Cardiovascular Medicine · doi:10.5083/ejcm.20424884.211
FDA Alert: Curtail High-Dose Simvastatin to Avoid Myopathy
FitzGerald, S. F. (2011) · Neurology Today · doi:10.1097/01.nt.0000403265.62198.e6
Rosselli, D., Castaño, N., & Peña, Á. A. G. (2015)
CANZANO, P. (2016) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/canzano-paola_phd2016-01-12
Statins: Risk-Benefits and Role in Treating Dyslipidemias
Gotto, A. M., & Moon, J. E. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_24
Osun, B., & Yoon, H. (2011) · Korean Journal of Clinical Pharmacy
Mehta, D., Hansen, G. L., Østigård, H., Bjørnstad, M., Pettersen, I., Salvesen, R. M., & Rollefstad, S. (2012)
Drugs for Elevated Low-Density Lipoprotein Cholesterol
Stone, N. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00024-2
Vitamin D Deficiency in Muscle
Abou‐Al‐Shaar, H., & Bohlega, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-29514-5_12
Statins Sharply Lower Cardiovascular Risk Regardless of Baseline LDL Cholesterol
Soloway, B. (2010) · Journal watch · doi:10.1056/jw201012160000001
Metadata
- Authors
- Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
- Corresponding author
- Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 376
- Issue
- 9753
- Pages
- 1658-1669
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2988223
- OpenAlex
- W1523152575
- Cited by
- 558
- References
- 38
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 20 · 2023: 23 · 2022: 28 · 2021: 22 · 2020: 29 · 2019: 31 · 2018: 33 · 2017: 35 · 2016: 40 · 2015: 47 · 2014: 52 · 2013: 50 · 2012: 68
- FWCI
- 61.00
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-01-08)
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- British Heart Foundation (PG/12/32/29544)
- University of Southampton
- University of Oxford
- Medical Research Council (MC_EX_G0801669)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- simvastatin, LDL cholesterol lowering, high-intensity statin therapy, myocardial infarction survivors, major vascular events, coronary artery disease, stroke, cardiovascular mortality, statin safety, lipid-lowering therapy, high cardiovascular risk patients, dose comparison, hemorrhagic stroke, coronary death, myocardial infarction recurrence, secondary prevention
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Triglycerides, Simvastatin, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
